NasdaqGS:MDGLBiotechs
Madrigal Pharmaceuticals (MDGL) Is Up 7.4% After EU Approval of Rezdiffra as First MASH Therapy
In August 2025, Madrigal Pharmaceuticals announced that the European Commission granted conditional marketing authorization for Rezdiffra (resmetirom), making it the first and only approved therapy in the EU for adults with noncirrhotic MASH with moderate to advanced liver fibrosis.
This decision positions Rezdiffra to address a substantial unmet need in Europe, where approximately 370,000 patients are currently diagnosed and managed by liver specialists.
We'll examine how becoming the sole...